Rizatriptan Tablet Versus Wafer: Patient Preference

Adelman, James U.; Mannix, Lisa K.; Seggern, Randal L. Von

doi:10.1046/j.1526-4610.2000.00055.x

Cited by 18 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients were equally satisfied with the efficacy of sumatriptan 100 mg and rizatriptan 10 mg Patients were also able to express preferences between different formulations of the triptans [36][37][38]40], although these data are biased due to the asymmetry of the treatment groups. Patients could even distinguish between different doses of oral sumatriptan [41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

Dowson

Tepper

Dahlöf³

2005

J Headache Pain

View full text Add to dashboard Cite

Oral triptans are effective and well tolerated acute treatments for migraine, but clinical differences between them are small and difficult to measure in conventional clinical trials. Patient preference assesses a global measure of efficacy and tolerability, and may be a more sensitive means of distinguishing between these drugs. In a series of studies, patients consistently expressed a clear preference for triptans over their usual non–triptan acute medications, e.g., analgesics and ergotamine. Direct comparator studies of patient preference with oral triptans showed that patients could distinguish between different triptans, and between different formulations of the same triptan. Patients could even distinguish between the three oral doses of sumatriptan. The most frequently provided reasons for preference were speed of response and overall effectiveness. Patient preference is a sensitive clinical trial endpoint and physicians should consider using it when reviewing the efficacy of acute migraine medications.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Patients (n=367) taking part in a clinical study of rizatriptan were allowed to continue open-label treatment with both the film-coated tablet and ODT formulations for a 6-month period [40]. At the end of the study, 51.2% preferred the ODT and 48.8% the film-coated tablet.…”

Section: Rizatriptanmentioning

confidence: 99%

Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

Dowson

Tepper

Dahlöf³

2005

J Headache Pain

View full text Add to dashboard Cite

show abstract

“…It is important to note that the most important reason for preference was that the wafer relieved headache pain faster than the tablet, rather than being simply due to the formulation. Indeed, in a retrospective investigation of patient preference in which patients were given free access to rizatriptan wafer and rizatriptan tablet over a 6-month period, no group preference was found (188 preferring the wafer while 179 preferred the conventional tablet) [10]. This may reflect that clinical trials not involving direct comparisons suggest that the rizatriptan tablet and wafer have similar clinical efficacy (2-hour pain-free rates of 42% for both tablet [11]and wafer [1]with placebo response rates of 10% in both studies).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Preference for Rizatriptan 10-mg Wafer versus Sumatriptan 50-mg Tablet in Migraine

et al. 2001

View full text Add to dashboard Cite

Rizatriptan (MAXALT^TM, a registered trademark of Merck & Co. Inc.) is a selective 5-HT_1B/1D receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized, open-label, crossover outpatient study assessed the preference of 481 patients for rizatriptan 10-mg rapidly disintegrating tablets versus sumatriptan (IMIGRAN^TM, a registered trademark of GlaxoWellcome PLC) 50-mg tablets in the treatment of a single migraine attack with each therapy. Almost twice as many patients preferred rizatriptan 10-mg rapidly disintegrating tablet to sumatriptan 50-mg tablet (64.3 vs. 35.7%, p ≤ 0.001). Faster relief of headache pain was the most important reason for the preference, cited by 46.9% of patients preferring rizatriptan and 43.4% of patients who preferred sumatriptan. Headache relief at 2 h was 75.9% with rizatriptan and 66.6% with sumatriptan (p ≤ 0.001), with rizatriptan being superior to sumatriptan within 30 min of dosing. Fifty-five percent of patients were pain free 2 h after rizatriptan, compared with 42.1% treated with sumatriptan (p ≤ 0.001), rizatriptan being superior within 1 h of treatment. Forty-one percent of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication, compared to 32.3% of patients on sumatriptan. Rizatriptan was also superior to sumatriptan in terms of the proportions of patients with no nausea, phonophobia or photophobia, and patients with normal function 2 h after treatment intake (p < 0.05). More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (73.3%) than 2 h after treatment with sumatriptan (59.0%) (p ≤ 0.001). Additionally, 2 h after the dose, more patients found rizatriptan to be very convenient, convenient or somewhat convenient (87.2%) than they did sumatriptan (76.3%) (p ≤ 0.001). Both active treatments were well tolerated. The most common side effects with rizatriptan and sumatriptan were nausea (6.6 and 6.9% of patients, respectively), dizziness (6.1 and 5.8%) and somnolence (7.4 and 6.7%).

show abstract

“…It is possible that treatment choice could have been influenced by the ease of use of the rizatriptan wafer formulation in these 2 studies. However, a relatively small percentage of patients reported this as the reason for treatment preference, and results of a separate retrospective nonblinded study in 367 patients showed that a similar number of patients preferred the 10-mg wafer (n = 188) and 10-mg tablet (n = 179) rizatriptan formulations (Adelman et al 2000), suggesting that formulation was probably not the key factor.…”

Section: Tolerability and Patient Acceptabilitymentioning

confidence: 99%

Rizatriptan in the treatment of migraine

Láinez

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Migraine is a common, disabling disorder associated with considerable personal and societal burden. Current guidelines recommend triptans for the acute treatment of migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers several advantages over other members of its class. Rizatriptan is rapidly absorbed from the gastrointestinal tract and achieves maximum plasma concentrations more quickly than other triptans, providing rapid pain relief. Clinical trials have shown that rizatriptan is at least as effective or superior to other oral migraine-specifi c agents in the acute treatment of migraine, and has more consistent long-term effi cacy across multiple migraine attacks. Rizatriptan has a favorable tolerability profi le, and patients have reported greater satisfaction and a preference for rizatriptan over other migraine-specifi c agents. Improvements in quality of life reported with rizatriptan are consistent with its favorable effi cacy and tolerability profi les. Notably, multi-attribute decision models that combine clinical data with patient-and physician-reported treatment preferences have identifi ed rizatriptan as one of three triptans closest to a hypothetical "ideal". The effi cacy and tolerability of rizatriptan for the acute treatment of migraine have thus been well established.

show abstract

Rizatriptan Tablet Versus Wafer: Patient Preference

Cited by 18 publications

References 7 publications

Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

Comparison of Preference for Rizatriptan 10-mg Wafer versus Sumatriptan 50-mg Tablet in Migraine

Rizatriptan in the treatment of migraine

Contact Info

Product

Resources

About